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Blood pressure instability during 
hemodialysis
DW Landry1 and JA Oliver1
Most patients with end-stage renal disease (ESRD) maintained on 
hemodialysis have chronic hypertension. However, hypotension is a 
frequent complication of hemodialysis, probably because of impaired 
baroreflex function. Less frequently, increases in pressure can be a 
complication of hemodialysis. Detailed studies of patients with these 
abnormalities in arterial pressure during hemodialysis may yield 
insights into the regulation of arterial pressure during ESRD.
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Blood pressure is frequently increased 
in end-stage renal disease (ESRD), and 
chronic hypertension contributes signifi -
cantly to the high incidence of cardiovas-
cular disease and the markedly reduced 
lifespan of hemodialysis patients.1,2 Vol-
ume expansion in ESRD is an important 
contributor to this hypertension, and, as 
a consequence, adequate control of blood 
pressure can be diffi  cult or impossible 
despite multidrug antihypertension regi-
mens.1–3 Th e endemic nature of persist-
ently high blood pressure in ESRD has 
a paradoxical eff ect on epidemiological 
studies: normotension and hypotension 
become surrogate markers for comor-
bid conditions with arterial underfi ll-
ing, such as congestive heart failure.4 
In this circumstance, lower blood pres-
sure correlates with poor outcome, and 
the association of high blood pressure 
with its clinical complications can be 
obscured. Nonetheless, clinical stud-
ies in hypertensive patients with ESRD 
show that improvement of the hyperten-
sion leads to a diminution of morbidity 
and mortality and that hypertension in 
ESRD is deleterious to health and inimi-
cal to long life.
However, if volume is a key element in 
the problem of chronic hypertension in 
ESRD, why is volume removal by hemo-
dialysis not an eff ective solution? Th e 
answer, generally, lies in the high inci-
dence of hypotension during hemodial-
ysis that limits removal of extracellular 
fl uid volume.1,5,6 Th e ‘dry weight’ goal for 
a dialysis treatment is empirically derived 
and refl ects the weight that just avoids 
precipitating symptomatic decreases 
in blood pressure.5,6 Th e refl exes of the 
hemodialysis nurse faced with sympto-
matic hypotension are telltale: the trans-
membrane potential is decreased, and 
intravenous saline is administered. Th e 
‘dry weight’ goal is thus raised, but at a 
cost of increased volume and hyperten-
sion between treatments.
Many potential etiologies are often 
listed for intradialytic hypotension, and 
this usually signals a hopeless morass.7 
However, one set of mechanisms occurs 
in a majority of patients with signifi cant 
frequency and therefore merits critical 
attention. Th e abrupt removal of fl uid by 
hemodialysis acutely decreases intravas-
cular volume and can compromise ven-
tricular preload. Depending on the rate 
of refi lling and any impairment of ven-
tricular compliance, cardiac output can 
decline, and the maintenance of blood 
pressure now hinges on a refl ex increase 
in systemic vascular resistance. However, 
for many patients this fl uid removal fre-
quently fails to elicit the systemic vaso-
constriction expected for acute decreases 
of blood volume, and occasionally, frank 
vasodilation is observed.8,9
Deranged regulation of vascular tone 
during hemodialysis is not generally 
related to a defect in the renin–angio-
tensin II or catecholamine response. 
Plasma renin activity rises during hemo-
dialysis with signifi cant fl uid removal, 
and plasma catecholamine levels fre-
quently increase. However, we recently 
implicated a role for vasopressin in the 
failure of systemic vascular resistance 
to increase with fluid removal during 
hemodialysis (S van der Zee et al., J 
Am Soc Nephrol 2003; 14: 41A, abstr.). 
We confirmed the observation that 
plasma vasopressin does not rise during 
hemodialysis with signifi cant ultrafi l-
tration and discovered that vasopressin 
administration stabilizes blood pressure. 
Vasopressin as a treatment for intradia-
lytic hypotension could, paradoxically, 
provide a treatment for hypertension 
between treatments: Improved control 
of extracellular volume overload may  
normalize blood pressure and improve 
the response to antihypertensive agents. 
Th e benefi ts from improved control of 
extracellular fl uid volume are suggested 
by the experience with extended-dura-
tion hemodialysis. Extended duration 
permits a decreased rate of fl uid removal 
and improves hemodynamic stability on 
hemodialysis, thus resulting in better 
extracellular fl uid control and dimin-
ished chronic hypertension.
A less common and much more 
obscure derangement of blood pressure 
control during hemodialysis in ESRD 
patients are increases in pressure; that is, 
intradialytic hypertension.10 Th is syn-
drome is the subject of investigation by 
Chou et al. in this issue.11 Fift een con-
trol patients and 15 hypertension-prone 
patients were studied. Th e baseline blood 
pressure in the hypertension group was 
significantly higher than that of the 
control and increased throughout the 
treatment. Th e blood volume declined 
signifi cantly in the control group but not 
the hypertensive group. Given compara-
ble ultrafi ltration volumes for the groups, 
this was consistent with faster refi lling of 
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the intravascular volume in the hyper-
tension-prone group. Th ese fi ndings sug-
gested the possibility that hypertension 
was driven by increased cardiac output. 
However, this was considered unlikely, 
because indirect determination of the 
cardiac output suggested that it decreased 
comparably in both groups and that sys-
temic vascular resistance increased in the 
hypertension-prone group.
Activation of the renin–angiotensin II 
system and activation of the sympathetic 
nervous system have been suggested as 
underlying defects for this syndrome, 
and renin, norepinephrine, and epine-
phrine were measured before and at the 
conclusion of dialysis. Th e control group 
showed the expected pattern with hemo-
dialysis and removal of more than 2 lit-
ers of fl uid: renin, norepinephrine, and 
epinephrine all rose signifi cantly.11 Inter-
estingly, these hormones did not increase 
in the hypertension-prone patients. Fur-
ther, an analysis of heart rate variability 
showed in controls, but not hypertension-
prone patients, a signifi cant elevation of 
the power index during the course of 
treatment that is indicative of increased 
sympathetic-to-parasympathetic activ-
ity. Neither increased hematocrit nor 
hypokalemia could explain the increase 
in resistance, and the authors suggest 
endothelial dysfunction with a nitric 
oxide–endothelin imbalance as a focus for 
future investigation. Vasopressin would 
also be a reasonable target for investiga-
tion, but, for now, the pathophysiology 
underlying increased resistance during 
hemodialysis with hypertension-prone 
patients remains a mystery.
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Detection of pattern of 
myocardial fibrosis by contrast-
enhanced MRI: Is redefinition 
of uremic cardiomyopathy 
necessary for management of 
patients?
J Aoki1 and K Hara1
Cardiac magnetic resonance imaging (CMR) can detect cardiac tissue 
components for several kinds of cardiac myopathies. Mark et al. found 
two patterns of late gadolinium enhancement (LGE) in patients with 
uremic cardiomyopathy: focal LGE and diffuse LGE. The impact of 
these contrast-enhanced CMR findings on clinical outcomes warrants 
assessment in future studies.
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Cardiovascular disease is the main cause 
of death in patients with end-stage renal 
failure and accounts for almost 40% of 
the deaths in this population.1 However, 
uremic cardiomyopathy has not been 
investigated in detail, and its etiology and 
pathophysiology are unclear. One study 
showed that the pathologic characteris-
tics of uremic cardiomyopathy are severe 
myocyte hypertrophy, occasionally with 
disarray, and a high percentage area of 
fi brosis, and the extent of left  ventricular 
fi brosis was a strong predictor of cardiac 
death.2 Th e causes of these pathologic 
changes may be associated with vol-
ume overload, pressure overload, mal-
nutrition, anemia, uremic toxins, high 
catecholamine levels, and hyperparathy-
roidism. Hypertrophy due to pressure 
and volume overload is associated with a 
distinct myocyte phenotype and diff eren-
tial induction of peptide growth factors, 
which may stimulate both the loss and 
the hypertrophic growth of myocytes. 
Collagen fibers and other interstitial 
matrix molecules increase during hyper-
trophy, followed by the loss of myocytes 
due to myocardial injury.
From a clinical point of view, it is 
important to assess the cardiac function 
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